ALVO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

164.93M

+7.56%

-0.033

+10.8%

141.54M

+6.58%

-0.004

-98.19%

Estimates Revision

The market is revising Downward the revenue expectations for Alvotech (ALVO) for FY2025, with the revenue forecasts being adjusted by -11.13% over the past three months. During the same period, the stock price has changed by -44.10%.

Revenue Estimates for FY2025

Revise Downward

-11.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-121.94%

In Past 3 Month

Stock Price

Go Down

-44.10%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ALVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALVO is 10.67 USD with a low forecast of 8.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

10.67

High

14.00

Current: 0.000

Low

8.00

Averages

10.67

High

14.00

Barclays

Glen Santangelo

Underweight

initiated

2025-12-08

Reason

Barclays

Glen Santangelo

Price Target

2025-12-08

initiated

Underweight

Reason

Barclays analyst Glen Santangelo initiated coverage of Alvotech with an Underweight rating and $5 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Morgan Stanley

Overweight

downgrade

$14 -> $10

2025-12-03

Reason

Morgan Stanley

Price Target

$14 -> $10

2025-12-03

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Alvotech to $10 from $14 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.

UBS

Buy

downgrade

$13 -> $10

2025-11-18

Reason

UBS

Price Target

$13 -> $10

2025-11-18

downgrade

Buy

Reason

UBS lowered the firm's price target on Alvotech to $10 from $13 and keeps a Buy rating on the shares.

Northland

Outperform

NULL

downgrade

$28 -> $10

2025-11-04

Reason

Northland

Price Target

$28 -> $10

2025-11-04

downgrade

Outperform

NULL

Reason

Northland lowered the firm's price target on Alvotech to $10 from $28 and keeps an Outperform rating on the shares after the company received a Complete Response Letter for AVT05 following FDA inspection findings at its Reykjavik site. The company lowered FY25 revenue and adjusted EBITDA guidance as a result, notes the firm, which expects outstanding BLAs for AVT03 and AVT06 to be delayed as well.

Deutsche Bank

Buy

Hold

downgrade

$14 -> $8

2025-11-04

Reason

Deutsche Bank

Price Target

$14 -> $8

2025-11-04

downgrade

Buy

Hold

Reason

Deutsche Bank downgraded Alvotech to Hold from Buy with a price target of $8, down from $14, after the company received a complete response letter from the FDA for AVT05. The CRL noted deficiencies from an FDA inspection of Alvotech's Reykjavik manufacturing facility, the analyst tells investors in a research note. After speaking to management, Deutsche says the issues identified by the FDA could also lead to CRLs for both the AVT03 and AVT06 launches.

Deutsche Bank

Niall Alexander

Buy

Hold

downgrade

2025-11-03

Reason

Deutsche Bank

Niall Alexander

Price Target

2025-11-03

downgrade

Buy

Hold

Reason

Deutsche Bank analyst Niall Alexander downgraded Alvotech to Hold from Buy with an $8 price target.

Valuation Metrics

The current forward P/E ratio for Alvotech SA (ALVO.O) is 35.79, compared to its 5-year average forward P/E of -18.62. For a more detailed relative valuation and DCF analysis to assess Alvotech SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.62

Current PE

35.79

Overvalued PE

200.03

Undervalued PE

-237.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.97

Current EV/EBITDA

11.93

Overvalued EV/EBITDA

25.81

Undervalued EV/EBITDA

-29.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.31

Current PS

2.21

Overvalued PS

11.91

Undervalued PS

0.71

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALVO News & Events

Events Timeline

No data

News

7.0

01-09Globenewswire

Alvotech Faces Allegations of Misleading Investors, Stock Plummets 34%

5.0

01-07Globenewswire

ATP Holdings Acquires 4.81M Shares in Alvotech at SEK 44.06

8.5

01-06Globenewswire

Alvogen Acquires 7,007,321 Shares in Alvotech at SEK 44.06 Each

People Also Watch

Frequently Asked Questions

What is Alvotech SA (ALVO) stock price today?

The current price of ALVO is 4.64 USD — it has decreased -1.9 % in the last trading day.

What is Alvotech SA (ALVO)'s business?

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

What is the price predicton of ALVO Stock?

What is Alvotech SA (ALVO)'s revenue for the last quarter?

Alvotech SA revenue for the last quarter amounts to 113.86M USD, increased 10.56 % YoY.

What is Alvotech SA (ALVO)'s earnings per share (EPS) for the last quarter?

Alvotech SA. EPS for the last quarter amounts to -0.02 USD, decreased -50.00 % YoY.

What changes have occurred in the market's expectations for Alvotech SA (ALVO)'s fundamentals?

How many employees does Alvotech SA (ALVO). have?

Alvotech SA (ALVO) has 1011 emplpoyees as of January 10 2026.

What is Alvotech SA (ALVO) market cap?

Today ALVO has the market capitalization of 1.45B USD.